South San Francisco, United States
Star Therapeutics, founded in 2018, is a clinical stage biotechnology company based in the United States. With a distinct vision encapsulated in its slogan, "In a universe of possibilities, we see things differently," the company is focused on discovering and developing best-in-class antibodies to create life-changing therapies for patients, primarily targeting unmet needs in hematology and immunology.
Star Therapeutics' lead program, VGA039, holds promise as a universal hemostatic therapy aimed at treating various bleeding disorders, beginning with von Willebrand disease. The therapy is notable for its potential to be subcutaneously self-administered, offering a more convenient dosing regimen that could significantly alleviate treatment burdens.
As of 05 September 2023, Star Therapeutics secured a $90.00M Series C investment. This funding round was backed by prominent investors, including New Leaf Venture Partners, RA Capital Management, Sofinnova Investments, and Qatar Investment Authority, among others. This robust backing underscores strong confidence in the company's innovative approach and long-term potential in the health care industry.
